Marcos Palatnik

List of Publications by Year
in descending order

20 papers	1,044 citations	471509 17 h-index	752698 20 g-index
20 all docs	20 docs citations	20 times ranked	868 citing authors

#	Article	IF	Citations
1	Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine, 2004, 22, 2234-2243.	3.8	121
2	A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sï¿½o) Tj ETQq0 0 0 rgBT /Overlock	3.8	102
3	Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine, 2002, 21, 30-43.	3.8	98
4	Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with LeishmuneÂ® in Brazilian endemic areas. Vaccine, 2009, 27, 3505-3512.	3.8	91
5	Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani. Vaccine, 1997, 15, 1024-1029.	3.8	84
6	Prevalence of Anti-Leishmania donovani Antibody Among Brazilian Blood Donors and Multiply Transfused Hemodialysis Patients. American Journal of Tropical Medicine and Hygiene, 1997, 57, 168-171.	1.4	67
7	IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis. Vaccine, 2003, 21, 2589-2597.	3.8	62
8	Leishmania donovani: titration of antibodies to the fucose-mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 390-393.	1.8	49
9	Adaptive Immunity against Leishmania Nucleoside Hydrolase Maps Its C-Terminal Domain as the Target of the CD4+ T Cellâ€Driven Protective Response. PLoS Neglected Tropical Diseases, 2010, 4, e866.	3.0	48
10	Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine, 2003, 21, 4668-4676.	3.8	44
11	Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani. Vaccine, 1999, 17, 2554-2561.	3.8	43
12	Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine, 2001, 19, 3104-3115.	3.8	43
13	A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection. Frontiers in Immunology, 2017, 8, 100.	4.8	35
14	Improving methods for epidemiological control of canine visceral leishmaniasis based on a mathematical model. Impact on the incidence of the canine and human disease. Anais Da Academia Brasileira De Ciencias, 2004, 76, 583-593.	0.8	35
15	Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains. Frontiers in Immunology, 2014, 5, 189.	4.8	31
16	Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis. Frontiers in Immunology, 2017, 8, 227.	4.8	27
17	Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection. Frontiers in Immunology, 2014, 5, 273.	4.8	22
18	Occurrence of Leishmania donovani parasitemia in plasma of infected hamsters. Acta Tropica, 2001, 80, 69-75.	2.0	16

#	Article	IF	Citations
19	The LeishmuneÂ®Ìs Nucleoside hydrolase DNA vaccine as an aid in immunotherapy of canine visceral leishmaniasis. Procedia in Vaccinology, 2012, 6, 64-73.	0.4	13
20	Resistance to visceral leishmaniasis is severely compromised in mice deficient of bradykinin B2-receptors. Parasites and Vectors, 2012, 5, 261.	2.5	13